VolitionRX Ltd (VNRX) CFO Acquires $50,000.00 in Stock
VolitionRX Ltd (NASDAQ:VNRX) CFO David Matthew Kratochvil bought 10,000 shares of the business’s stock in a transaction dated Wednesday, October 5th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $50,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $50,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of VolitionRX Ltd (NASDAQ:VNRX) traded up 4.93% during mid-day trading on Thursday, reaching $5.11. The company had a trading volume of 79,638 shares. VolitionRX Ltd has a 1-year low of $3.05 and a 1-year high of $5.86. The firm has a 50-day moving average price of $4.50 and a 200-day moving average price of $3.70. The stock’s market capitalization is $120.19 million.
VolitionRX (NASDAQ:VNRX) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. Equities analysts expect that VolitionRX Ltd will post ($0.56) earnings per share for the current year.
A number of brokerages recently commented on VNRX. HC Wainwright set a $10.00 price target on VolitionRX and gave the stock a “buy” rating in a research note on Thursday, September 8th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $10.00 price target (down previously from $12.00) on shares of VolitionRX in a research note on Wednesday, September 7th.
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Receive News & Stock Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related stocks with our FREE daily email newsletter.